Schiff Nutrition International (WNI) 10-Q 2003 Q3 Quarterly report

QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended August 31, 2003
o	TRANSITION REPORT PURSUANT TO SECTION 12 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                             to

Commission file number:
001-14608

WEIDER NUTRITION INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	87-0563574 (I.R.S. Employer Identification No.)
2002 South 5070 West Salt Lake City, Utah (Address of principal executive offices)	84104-4726 (Zip Code)
Registrant's telephone number, including area code: (801) 975-5000

        Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o

        Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes o    No ý

        The number of shares outstanding of the Registrant's common stock is 26,735,402 (as of October 1, 2003).

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

WEIDER NUTRITION INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

				August 31, 2003			May 31, 2003
				(unaudited)
ASSETS
Current assets:
	Cash and cash equivalents			$	4,764		$	3,463
	Receivables, net				31,532			27,592
	Inventories				29,379			27,543
	Prepaid expenses and other				2,684			4,312
	Deferred taxes				3,242			2,908
	Assets held for sale				—			5,077
		Total current assets			71,601			70,895
Property and equipment, net					26,124			26,676
Other assets:
	Intangible assets, net				9,719			9,738
	Deposits and other assets				5,176			5,286
	Notes receivable, net				2,335			2,178
	Assets held for sale				—			469
		Total other assets			17,230			17,671
			Total assets	$	114,955		$	115,242
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
	Accounts payable			$	22,509		$	20,096
	Accrued expenses				13,508			16,610
	Current portion of long-term debt				4,556			8,057
	Income taxes payable				139			173
		Total current liabilities			40,712			44,936
Long-term debt					388			659
Deferred taxes					2,361			801
Commitments and contingencies (Note 8)
Stockholders' equity:
	Preferred stock, par value $.01 per share; shares authorized—10,000,000; no shares issued and outstanding				—			—
	Class A common stock, par value $.01 per share; shares authorized—50,000,000; shares issued and outstanding—11,762,254 and 11,916,288				118			119
	Class B common stock, par value $.01 per share; shares authorized—25,000,000; shares issued and outstanding—14,973,148				150			150
	Additional paid-in capital				86,488			86,943
	Deferred compensation costs				(799	)		(873	)
	Other accumulated comprehensive loss				(4,116	)		(4,951	)
	Retained deficit				(10,347	)		(12,542	)
		Total stockholders' equity			71,494			68,846
			Total liabilities and stockholders' equity	$	114,955		$	115,242

See notes to condensed consolidated financial statements.

2

WEIDER NUTRITION INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share data)
(unaudited)

			Three Months Ended August 31,
			2003			2002
Net sales			$	63,641		$	69,328
Cost of goods sold				39,348			41,215
Gross profit				24,293			28,113
Operating expenses:
	Selling and marketing			14,496			11,677
	General and administrative			5,383			6,228
	Research and development			1,214			873
	Amortization of intangible assets			142			302
		Total operating expenses		21,235			19,080
Income from operations				3,058			9,033
Other income (expense):
	Interest income			147			20
	Interest expense			(333	)		(928	)
	Other			(155	)		307
		Total other expense, net		(341	)		(601	)
Income from continuing operations before income taxes				2,717			8,432
Income tax expense				1,088			3,373
Net income from continuing operations				1,629			5,059
Income (loss) from discontinued operations, net of income taxes				566			(571	)
Net income before cumulative effect of change in accounting principle				2,195			4,488
Cumulative effect of change in accounting principle, net of income tax benefit				—			(15,392	)
Net income (loss)			$	2,195		$	(10,904	)
Weighted average shares outstanding:
	Basic			26,237,002			26,249,436
	Diluted			26,744,821			26,301,395
Net income (loss) per share—basic and diluted:
	Net income from continuing operations		$	0.06		$	0.19
	Net income (loss) from discontinued operations			0.02			(0.02	)
	Net income before cumulative effect of change in accounting principle			0.08			0.17
	Cumulative effect of change in accounting principle			—			(0.59	)
	Net income (loss)		$	0.08		$	(0.42	)
Comprehensive income (loss)			$	3,030		$	(10,524	)

See notes to condensed consolidated financial statements.

3

WEIDER NUTRITION INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(dollars in thousands)
(unaudited)

				Three Months Ended August 31,
				2003			2002
Cash flows from operating activities:
	Net income (loss)			$	2,195		$	(10,904	)
	Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
		Provision for (recovery of) bad debts			(455	)		285
		Deferred taxes			1,226			(4,740	)
		Depreciation and amortization			1,225			1,650
		Asset impairment			—			23,321
		Gain on sale of assets held for sale and property and equipment			(950	)		—
		Amortization of financing fees, including original issue discount			102			276
		Amortization of deferred compensation costs			24			—
	Changes in operating assets and liabilities:
		Receivables			(4,019	)		2,181
		Inventories			(1,836	)		(4,422	)
		Prepaid expenses and other			1,628			705
		Deposits and other assets			(54	)		(204	)
		Accounts payable			2,414			(333	)
		Other current liabilities			(2,388	)		(3,179	)
			Net cash provided by (used in) operating activities		(888	)		4,636
Cash flows from investing activities:
	Purchase of property and equipment				(330	)		(402	)
	Purchase of intangibles				—			(34	)
	Proceeds from disposition of assets held for sale				6,510			5,400
	Proceeds from sale of available-for-sale equity securities				—			1,002
	Collection of notes receivable				4			—
			Net cash provided by investing activities		6,184			5,966
Cash flows from financing activities:
	Net change in revolving line-of-credit				50			(11,332	)
	Proceeds from debt				109			5,501
	Payments on debt				(4,256	)		(4,179	)
			Net cash used in financing activities		(4,097	)		(10,010	)
Effect of exchange rate changes on cash					102			167
Increase in cash and cash equivalents					1,301			759
Cash and cash equivalents, beginning of period					3,463			2,412
Cash and cash equivalents, end of period				$	4,764		$	3,171

See notes to condensed consolidated financial statements.

4

WEIDER NUTRITION INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share data)
(unaudited)

1. BASIS OF PRESENTATION AND OTHER MATTERS

        The accompanying unaudited interim condensed consolidated financial statements ("interim financial statements") do not include all disclosures provided in our annual consolidated financial statements. These interim financial statements should be read in conjunction with the consolidated financial statements and the footnotes thereto contained in our Annual Report on Form 10-K for the year ended May 31, 2003 as filed with the Securities and Exchange Commission. The May 31, 2003 consolidated balance sheet was derived from audited financial statements, but all disclosures required by generally accepted accounting principles are not provided in the accompanying footnotes. We are a majority-owned subsidiary of Weider Health and Fitness ("WHF").

        In our opinion, the accompanying interim financial statements contain all adjustments (which are of a normal recurring nature) necessary for a fair presentation of our financial position and results of operations. Certain prior period amounts have been reclassified to conform with the current interim period presentation. The results of operations and cash flows for any interim period are not necessarily indicative of the results of operations and cash flows that we may achieve for any other interim period or for the entire year.

        Effective in our fiscal 2004 first quarter, we sold the assets of our Haleko Venice Beach® sports apparel business to Hucke AG, a German apparel company, for net cash proceeds of approximately $6,510. In accordance with Statement of Financial Accounting Standards ("SFAS") No. 144, the operating results for Venice Beach® are reflected as discontinued operations and the associated assets are included in assets held for sale in the accompanying condensed consolidated financial statements. We recognized an after-tax gain on the sale of approximately $578, which is included in income from discontinued operations. The gain may subsequently be impacted by severance and/or certain lease related costs, as well as the final reconciliation of assets sold in the transaction.

        Effective August 16, 2002, we issued 640,000 restricted shares of Class A common stock to certain officers and employees. The aggregate value of the restricted shares was approximately $1,038, which we are expensing on a straight-line basis over the accompanying five-year vesting period. In August 2003, 13,600 of these restricted shares were cancelled as a result of the voluntary termination of certain employees.

        On July 26, 2002, we sold substantially all of the assets and certain associated liabilities relating to our American Body Building® and Science Foods® brands. The impact of the sale on the fiscal 2003 first quarter operating results was not significant.

        Effective June 1, 2002, we adopted SFAS No. 142, "Goodwill and Other Intangible Assets", which establishes new accounting and reporting standards for goodwill and other intangible assets. (See Note 4 to Condensed Consolidated Financial Statements).

        We disclose the effect of SFAS No. 123 "Accounting for Stock-Based Compensation", on a proforma basis and continue to follow Accounting Principles Board ("APB") Opinion No. 25 (as permitted by SFAS No. 123) as it relates to stock based compensation.

        Proforma information regarding net income (loss) and net income (loss) per share is required by SFAS No. 123, as amended by SFAS No. 148, and has been determined as if we had accounted for our employee stock options and previously unvested performance units under the fair value method of SFAS No. 123. For the purposes of proforma disclosure, the estimated fair value of the stock options is

5

amortized to expense over the options vesting period. Our proforma net income (loss) and net income (loss) per share were as follows:

	2003		2002
Net income (loss), as reported	$	2,195	$	(10,904	)
Net income (loss), proforma		2,151		(10,919	)
Basic net income (loss) per share, as reported		.08		(.42	)
Diluted net income (loss) per share, as reported		.08		(.42	)
Basic net income (loss) per share, proforma		.08		(.42	)
Diluted net income (loss) per share, proforma		.08		(.42	)

2. RECEIVABLES, NET

        Receivables, net, consist of the following:

		August 31, 2003			May 31, 2003
Trade accounts		$	38,821		$	35,242
Other, including income taxes			704			670
			39,525			35,912
Less allowance for doubtful accounts and sales returns			(7,993	)		(8,320	)
	Total	$	31,532		$	27,592

3. INVENTORIES

        Inventories consist of the following:

		August 31, 2003		May 31, 2003
Raw materials		$	10,488	$	8,487
Work in process			2,664		1,691
Finished goods			16,227		17,365
	Total	$	29,379	$	27,543

6

4. INTANGIBLE ASSETS, NET

        Intangible assets, net, consist of the following:

	August 31, 2003							May 31, 2003
	Gross Carrying Amount		Accumul. Amortiz.			Net Book Value		Gross Carrying Amount		Accumul. Amortiz.			Net Book Value
Patents and trademarks	$	9,904	$	(4,531	)	$	5,373	$	9,743	$	(4,351	)	$	5,392
Goodwill		4,346		—			4,346		4,346		—			4,346
	$	14,250	$	(4,531	)	$	9,719	$	14,089	$	(4,351	)	$	9,738

        Estimated amortization expense, assuming no changes in our intangible assets, for each of the five succeeding fiscal years, beginning with fiscal 2004, is $553 (2004), $407 (2005), $407 (2006), $387 (2007), and $363 (2008).

        Upon the implementation of SFAS No. 142, we tested goodwill for impairment by comparing the carrying amount, including goodwill, for each of our reporting (business) units at June 1, 2002 to the estimated fair value for each of our reporting units. We assessed the fair value of the reporting units by evaluating their current and future cash flows in comparison to our overall market capitalization. Based on this comparison, we concluded that the net book carrying value for two of our reporting units, Active Nutrition and Haleko, exceeded their respective fair values. For those two reporting units, we then compared the implied fair value of their respective goodwill to their respective net book carrying values to determine the asset impairment amount. Based on this comparison, effective June 1, 2002, we recognized an impairment loss of $23,321, or an after-tax charge of $15,392, as a cumulative effect of a change in accounting principle.

        The changes in the carrying amount of goodwill, broken down by business unit, for fiscal 2003 is as follows:

	Schiff® Specialty		Active Nutrition			Haleko			Total
Balance at June 1, 2002	$	4,346	$	1,843		$	21,478		$	27,667
Adoption of SFAS No. 142		—		(1,843	)		(21,478	)		(23,321	)
Balance at May 31, 2003	$	4,346	$	—		$	—		$	4,346

        The carrying amount of goodwill did not change during the first three months of fiscal 2004.

5. NOTES RECEIVABLE, NET

        Notes receivable (including accrued interest), net, were $2,335 and $2,178, respectively, at August 31, 2003 and May 31, 2003. The original notes receivable are recourse, generally collateralized by debtors' shares of our Class A common stock and are repayable beginning in June 2002 and ending December 2006.

        At present, in connection with collection efforts and in consideration of potential unrealizable amounts, we are pursuing negotiations with the debtors who are no longer employed by the company.

7

During the first quarter of fiscal 2004, we received $68 in cash and acquired and retired 140,434 shares of our Class A common stock valued at approximately $434 as payment of principal and accrued interest for two of the notes. As a result of on going discussions, the terms of the remaining notes, including maturity, interest rate and required collateral, have been, or may be modified. Certain allowances for, or adjustments to, unrealizable amounts are recognized to adjust the outstanding balances to the underlying collateral value and/or to consider other factors that may impact the valuation of the notes receivable.

        Recognition of future provision(s) for unrealizable amounts, or reductions in allowances for unrealizable amounts, will depend on, among other considerations, the fair value of our Class A common stock. In the event that shares of common stock are received in lieu of future cash payment, a portion of, or the entire net book value of the notes receivable may subsequently be reclassified as treasury stock and/or reflected as a direct reduction of capital within stockholders' equity. Notes receivable balances are reflected net of aggregate allowances for unrealizable amounts of $714 and $1,304, respectively, at August 31, 2003 and May 31, 2003.

6. OPERATING SEGMENTS

        Our operations are organized into three business units. These business units are the Schiff® Specialty Unit, the Active Nutrition Unit and the Haleko Unit (our primary European subsidiary). The business units are managed independently, each with its own sales and marketing resources, and supported by product research and development, operations and technical services, and administrative functions.

        We manufacture and market nutritional products, including a full line of specialty supplements, vitamins and minerals through our Schiff® Specialty Unit. Schiff® Specialty Unit products are marketed primarily in the United States through mass-market distribution channels. We manufacture and market a variety of sports nutrition, nutritional bar and weight management products through our Active Nutrition Unit. Active Nutrition Unit products are marketed domestically and internationally primarily through mass market and health club and gym distribution channels. We also manufacture and market nutritional products, including a full line of sports nutrition supplements, together with certain other nutraceuticals within our Haleko Unit. Haleko Unit products are marketed primarily in Europe through mass market and health club and gym distribution channels.

        The accounting policies of these business units are the same as those described in Note 1 to the consolidated financial statements in our Annual Report on Form 10-K. We evaluate the performance of our business units based on actual and expected operating results of the respective business units. Certain domestic assets are not allocated to the Schiff® Specialty and Active Nutrition Units. Accordingly, asset segment information is provided on a total domestic and non-domestic basis consistent with the manner in which management evaluates the business.

8

��       Segment information for the three months ended August 31, 2003 and 2002 is summarized as follows:

		Net Sales			Income (Loss) From Operations			Interest Expense
2003:
	Schiff® Specialty	$	39,032		$	3,012		$	201
	Active Nutrition		9,423			(138	)		20
	Haleko		16,519			160			130
	Eliminations		(1,333	)		24			(18	)
		$	63,641		$	3,058		$	333
2002:
	Schiff® Specialty	$	41,248		$	7,849		$	686
	Active Nutrition		11,865			939			81
	Haleko		17,168			245			161
	Eliminations		(953	)		—			—
		$	69,328		$	9,033		$	928

        Reconciliation of total assets for domestic and international operations is as follows:

		August 31, 2003			May 31, 2003
Total domestic assets		$	130,047		$	128,420
Total international assets			46,643			49,101
Eliminations			(61,735	)		(62,279	)
	Total	$	114,955		$	115,242

        Capital expenditures for domestic and international operations were $157 and $173, respectively, for the three months ended August 31, 2003, and $201 and $201, respectively, for the three months ended August 31, 2002.

7. SALES TO MAJOR CUSTOMERS

        Our two largest customers combined, accounted for approximately 53% and 50%, respectively, of net sales for the three months ended August 31, 2003 and 2002. At August 31, 2003, and May 31, 2003, amounts due from these customers represented approximately 38% and 39%, respectively, of total trade accounts receivable.

8. CONTINGENCIES

        In September 2003, we were named as a defendant inFant v. Weider Nutrition International, Inc. et. al. filed in North Carolina state court. The lawsuit alleges that the consumption of one of our former

9

ephedra products in October 2000 caused injuries and damages to the plaintiff. We dispute the allegations and are opposing the lawsuit. We have tendered the matter to our insurance carriers, which have not yet assumed defense of the matter. We can give no assurance that this lawsuit will be covered by our insurance. Discovery in this matter has not yet commenced.

        In September 2003, we were named as a defendant inBorgese v. Muscletech, Inc., Weider Nutrition International, Inc. et. al. filed in New Jersey state court. The lawsuit alleges that the consumption in 2001 of various products containing ephedra (distributed by several different companies) caused injuries and damages to the plaintiff. We dispute the allegations and are opposing the lawsuit. We have tendered the matter to our insurance carriers, which have not yet assumed defense of the matter. We can give no assurance that this lawsuit will be covered by our insurance. Discovery in this matter has not yet commenced.

        In September 2003, the Kansas Supreme Court denied the plaintiff's appeal inGarret v. Weider Nutrition International, Inc. et. al. Accordingly, we now consider this case to be closed.

        We are currently named as a defendant in three other lawsuits alleging that consumption of certain of our former products containing ephedra caused injuries and damages to certain individuals. We dispute the allegations and are opposing the lawsuits. Our insurance carriers have assumed the defense of two of the matters.

        We are also currently named as a defendant, along with numerous other dietary supplement companies, in purported class actions in certain state courts alleging that the defendants sold androstenedione and other purportedly similar products in violation of certain statutes and utilizing false and misleading claims and advertising. We dispute the allegations and are opposing the lawsuits.

        From time to time, we are involved in other claims, legal actions and governmental proceedings that arise from our business operations. Although ultimate liability cannot be determined at the present time, we believe that liability resulting from these matters, if any, after taking into consideration our insurance coverage, will not have a material adverse effect on our financial statements.

9. RECENTLY ISSUED ACCOUNTING STANDARDS

        In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated With Exit or Disposal Activities", which requires that costs associated with an exit or disposal activity be recognized when the liability is incurred and nullifies EITF No. 94-3. SFAS No. 146 is effective for any exit or disposal activities occurring after December 31, 2002. The requirements of SFAS No. 146 were applied in the accounting treatment for the disposition of Venice Beach® assets.

        In November 2002, the FASB issued Interpretation No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness to Others" ("FIN No. 45"), which addresses the disclosure to be made by a guarantor in its interim and annual financial statements about its obligations under guarantees. FIN No. 45 also requires the guarantor to recognize a liability for the non-contingent component of the guarantee, which is the obligation to stand ready to perform in the event that specified triggering events or conditions occur. The recognition and measurement provisions of FIN No. 45 are effective for all guarantees entered into or

10

modified after December 31, 2002. We have not entered into any such guarantees and therefore the adoption of this standard did not impact our consolidated financial statements.

        In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based Compensation—Transition and Disclosure—an amendment of SFAS No. 123". SFAS No. 148 amends SFAS No. 123, "Accounting for Stock-Based Compensation", to require disclosure in the summary of significant accounting policies of the effects of an entity's accounting policy with respect to stock-based employee compensation on reported net income and earnings per share in annual and interim financial statements. We have adopted the disclosure provisions of SFAS No. 148.

        In January 2003, the FASB issued Interpretation No. 46, "Consolidation of Variable Interest Entities", ("FIN No. 46") an interpretation of ARB No. 51. FIN No. 46 addresses consolidation by business enterprises of variable interest entities. FIN No. 46 applies immediately to variable interest entities created after January 31, 2003 and to variable interest entities in which an enterprise obtains and interest after that date. FIN No. 46 applies in the first year or interim period beginning after June 15, 2003 to variable interest entities in which an enterprise holds a variable interest that it acquired before February 1, 2003. We have not yet determined the impact of implementing FIN No. 46 on our consolidated financial statements.

        In April 2003, the FASB issued SFAS No. 149, "Amendment of Statement 133 on Derivative Instruments and Hedging Activities", which amends and clarifies accounting for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities under SFAS No. 133. SFAS No. 149 is effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003. The adoption of SFAS No. 149 did not have an impact on our consolidated financial statements.

        In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial Instruments with Characteristics of both Liability and Equity", which establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liability and equity in its statement of financial position. SFAS No. 150 is effective for new or modified financial instruments beginning June 1, 2003, and for existing instruments beginning August 1, 2003. We do not believe that the adoption of SFAS No. 150 will have an impact on our consolidated financial statements.

11

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

        The following discussion and analysis should be read in conjunction with the consolidated financial statements, including the notes thereto, appearing elsewhere in this Quarterly Report on Form 10-Q. We disclaim any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

General

        Weider Nutrition International, Inc. develops, manufactures, markets, distributes and sells branded and private label vitamins, nutritional supplements and sports nutrition products in the United States and throughout the world. We offer a broad range of capsules and tablets, powdered drink mixes, ready-to-drink beverages and nutrition bars consisting of approximately 800 stock keeping units ("SKUs"). Our portfolio of brands, including Schiff®, Weider®, Tiger's Milk®, Multipower® and Multaben, are primarily marketed through mass market, health food store and health club and gym distribution channels. We market our branded nutritional supplement products, both domestically and internationally, in five principal categories: specialty supplements; vitamins and minerals; sports nutrition; weight management; and nutrition bars.

        Effective in our fiscal 2004 first quarter, we sold substantially all of the assets relating to Haleko's Germany-based Venice Beach® sports apparel brand. The transaction included the sale of Venice Beach® receivables, inventories, intellectual property and certain fixed assets and the assumption by the purchaser of approximately 47 Venice Beach® employees. The net cash proceeds from the sale were approximately $6.5 million. In accordance with SFAS No. 144, operating results for Venice Beach® are reflected as discontinued operations for all periods presented.

        Our principal executive offices are located at 2002 South 5070 West, Salt Lake City, Utah 84104 and our telephone number is (801) 975-5000.

        Looking forward, our priorities include initiatives to defend our Schiff® Move Free® business against competition, including private label, and ultimately to increase our market share in the joint care product category. Accordingly, we expect to continue implementation of these initiatives for our Schiff® Move Free® business during fiscal 2004. While the focus of these considerations is to improve future profitability, no assurance can be given that our decisions relating to these initiatives will not adversely effect our results of operations or financial condition.

Results of Operations (Unaudited)

Three Months Ended August 31, 2003 Compared to Three Months Ended August 31, 2002

        The following tables show comparative results for continuing operations, by business unit, for the three months ended August 31, 2003 and 2002. Certain indirect costs, including primarily general and

12

administrative and research and development expenses, are charged to the business units based on various allocation methodologies (in thousands).

				Schiff® Specialty		Active Nutrition			Haleko		Other (1)			Total
2003:
	Net sales			$	39,032	$	9,423		$	16,519	$	(1,333	)	$	63,641
	Cost of goods sold				25,321		5,323			10,037		(1,333	)		39,348
	Gross profit				13,711		4,100			6,482		—			24,293
	Operating expenses:
		Selling and marketing			6,886		3,068			4,542		—			14,496
		General and administrative			2,939		925			1,519		—			5,383
		Research and development			853		177			184		—			1,214
		Amortization of intangible assets			21		68			77		(24	)		142
			Total operating expenses		10,699		4,238			6,322		(24	)		21,235
	Income (loss) from operations			$	3,012	$	(138	)	$	160	$	24		$	3,058
2002:
	Net sales			$	41,248	$	11,865		$	17,168	$	(953	)	$	69,328
	Cost of goods sold				24,951		6,839			10,378		(953	)		41,215
	Gross profit				16,297		5,026			6,790		—			28,113
	Operating expenses:
		Selling and marketing			4,509		2,790			4,378		—			11,677
		General and administrative			3,233		1,007			1,988		—			6,228
		Research and development			625		135			113		—			873
		Amortization of intangible assets			81		155			66		—			302
			Total operating expenses		8,448		4,087			6,545		—			19,080
	Income from operations			$	7,849	$	939		$	245	$	—		$	9,033

(1)

Amounts include inter-business unit sales eliminations and unallocated amounts.

        Net Sales.    Net sales decreased approximately 8.2% to $63.6 million for the fiscal 2004 first quarter, from $69.3 million for the fiscal 2003 first quarter. Overall, the decrease in net sales was primarily attributable to the fiscal 2003 first quarter sale of our American Body Building and Science Foods brands and a reduction in both Schiff® Specialty and Haleko private label sales.

        Schiff® Specialty net sales decreased approximately 5.4% to $39.0 million for the fiscal 2004 first quarter, from $41.2 million for the fiscal 2003 first quarter. The decrease primarily resulted from reductions in private label net sales, and a slight decrease in Schiff® Move Free® sales. Private label net sales were $12.1 million for the fiscal 2004 first quarter, compared to $13.2 million for the fiscal 2003 first quarter. The decrease was primarily attributable to customer ordering patterns and reduced pricing. Net sales of Schiff® Move Free® were $18.1 million for the fiscal 2004 first quarter, compared to $18.7 million for the fiscal 2003 first quarter.

        Active Nutrition net sales decreased approximately 20.6% to $9.4 million for the fiscal 2004 first quarter, from $11.9 million for the fiscal 2003 first quarter. The decrease was primarily attributable to the sale of our American Body Building® and Science Foods® brands, partially offset by the inclusion of Weider Germany sales volumes in Active Nutrition in fiscal 2004 (previously included in Haleko in fiscal 2003). Net sales of American Body Building™ and Science Foods® brands were $3.1 million for the fiscal 2003 first quarter.

13

        Haleko net sales decreased approximately 3.8% to $16.5 million for the fiscal 2004 first quarter, from $17.2 million for the fiscal 2003 first quarter. The decrease primarily resulted from a decline in private label sales volume. Economic conditions in Germany continue to decline and may negatively impact operating results in our Haleko business unit for the foreseeable future.

        Gross Profit.    Gross profit decreased approximately 13.6% to $24.3 million for the fiscal 2004 first quarter, from $28.1 million for the fiscal 2003 first quarter. The decrease primarily resulted from a decrease in sales, including reduced margins on Schiff® Specialty private label revenues. Gross profit, as a percentage of net sales, was 38.2% for the fiscal 2004 first quarter, compared to 40.6% for the fiscal 2003 first quarter. Gross profit percentage decreased in our Schiff® Specialty business unit, increased modestly in our Active Nutrition unit and remained relatively constant in our Haleko unit.

        Schiff® Specialty gross profit decreased approximately 15.9% to $13.7 million for the fiscal 2004 first quarter, from $16.3 million for the fiscal 2003 first quarter. Gross profit, as a percentage of net sales, was 35.1% for the fiscal 2004 first quarter, compared to 39.5% for the fiscal 2003 first quarter. The decrease resulted primarily from reduced margins on private label sales volumes due to a reduction in pricing resulting from competitive pressures.

        Active Nutrition gross profit decreased approximately 18.4% to $4.1 million for the fiscal 2004 first quarter, from $5.0 million for the fiscal 2003 first quarter, primarily resulting from a decrease in sales. Gross profit, as a percentage of net sales, was 43.5% for the fiscal 2004 first quarter, compared to 42.4% for the fiscal 2003 first quarter. The increase was primarily attributable to the elimination of lower-margin American Body Building® and Science Foods® brands and an increase in higher-margin export sales.

        Haleko gross profit decreased approximately 4.5% to $6.5 million for the fiscal 2004 first quarter, from $6.8 million for the fiscal 2003 first quarter. Gross profit, as a percentage of net sales, remained relatively constant at 39.2% and 39.6%, respectively, for the fiscal 2004 and 2003 first quarters.

        Operating Expenses.    Operating expenses increased approximately 11.3% to $21.2 million for the fiscal 2004 first quarter, from $19.1 million for the fiscal 2003 first quarter. Operating expenses, as a percentage of net sales, were 33.4% and 27.5%, respectively, for the fiscal 2004 and 2003 first quarters. The increase in operating expenses, as a percentage of net sales, was primarily attributable to increases in selling and marketing costs in support of our brand building initiatives for all business units, but particularly relating to our Schiff® Move Free® and other joint health products.

        Selling and marketing expenses, including sales, marketing, advertising, freight and other costs, were $14.5 million for the fiscal 2004 first quarter, compared to $11.7 million for the fiscal 2003 first quarter. The increase in selling and marketing expenses resulted primarily from incremental transition and marketing costs associated with our long-term Move Free® strategy, and increased selling and marketing in support of new products in our Schiff® Specialty and Active Nutrition business units.

        General and administrative expenses decreased to $5.4 million for the fiscal 2004 first quarter, from $6.2 million for the fiscal 2003 first quarter, primarily resulting from Haleko infrastructure efficiencies and a decrease in provisions for potentially unrealizable amounts due on notes receivable.

        Research and development costs were $1.2 million for the fiscal 2004 first quarter, compared to $0.9 million for the fiscal 2003 first quarter, primarily resulting from an increase in contracted product research costs.

        Other Expense.    Other expense, net, was $0.3 million for the fiscal 2004 first quarter, compared to $0.6 million for the fiscal 2003 first quarter. The decrease was primarily due to a reduction in interest expense resulting from less total indebtedness, partially offset by income recognized in the fiscal 2003 first quarter on the sale of certain held-for-sale equity securities.

14

        Provision for Income Taxes.    Provision for income taxes was a $1.1 million expense for the fiscal 2004 first quarter, compared to a $3.4 million expense for the fiscal 2003 first quarter. The change resulted primarily from the decrease in pre-tax earnings.

Liquidity and Capital Resources

        Working capital increased $4.9 million to approximately $30.9 million at August 31, 2003, from $26.0 million at May 31, 2003. The increase in working capital resulted primarily from a decrease in short-term borrowings and certain accrued expenses, partially offset by the sale of our Venice Beach® sports apparel business. An increase in net receivables, resulting primarily from higher sales in the fiscal 2004 first quarter, as compared to the fiscal 2003 fourth quarter, also contributed to the increase in working capital.

   ��    We entered into a senior credit facility (the "Credit Facility") with Bankers Trust Company, effective June 30, 2000, on behalf of our domestic subsidiaries. The Credit Facility, as subsequently amended, is comprised of a $45.0 million revolving loan. Under the revolving loan, we may borrow up to the lesser of $45.0 million or the sum of (i) 85% of eligible accounts receivable and (ii) the lesser of $22.5 million or 65% of the eligible inventory. The Credit Facility contains customary terms and conditions, including, among others, financial covenants regarding minimum cash flows and limitations on indebtedness and our ability to pay dividends under certain circumstances. Our obligations under the Credit Facility are secured by a first priority lien on all owned or acquired tangible and intangible assets of our domestic subsidiaries. The Credit Facility, which expires in March 2005, is being used to fund our normal working capital and capital expenditure requirements. At August 31, 2003, available revolving loan funds were approximately $21.8 million.

        Our domestic operations were also supported by a subordinated loan (the "Subordinated Loan") obtained in conjunction with the Credit Facility. The Subordinated Loan, in the original amount of $10.0 million, contained customary terms and conditions, including, among others, financial covenants regarding minimum cash flows and limitations on indebtedness and our ability to pay dividends under certain circumstances. Effective May 31, 2002, we used funds available under our revolving loan to pay down $5.0 million of the Subordinated Loan. Effective November 27, 2002, we used funds available under our revolving loan to pay-off the remaining $5.0 million of the Subordinated Loan.

        Our European working capital needs (primarily our Haleko business unit) are supported by a Germany-based secured credit facility (the "Haleko Facility") that is subject to annual renewal in June. Our obligations under the Haleko Facility are secured by a first priority lien on substantially all Haleko tangible and intangible assets. During June 2003, we renewed the Haleko Facility with Deutsche Bank AG in the approximate amount of $11.3 million (at recent exchange rate). Net proceeds from the sale of our Venice Beach® sports apparel business were used to repay a portion of our outstanding indebtedness under the Haleko Facility. At August 31, 2003, the outstanding balance of the Haleko Facility was approximately $2.6 million and available revolving loan funds were approximately $8.4 million.

        We believe that our cash, cash flows from operations and the financing sources discussed above will be sufficient to meet our normal cash operating requirements during the next twelve months. However, we continue to review opportunities to acquire or invest in companies, product rights and other investments that are compatible with our existing business. We could use cash and financing sources discussed herein, or financing sources that subsequently become available, to fund additional acquisitions or investments. In addition, we may consider issuing additional debt or equity securities in the future to fund potential acquisitions or growth, or to refinance existing debt. If a material acquisition or investment is completed, our operating results and financial condition could change materially in future periods. However, no assurance can be given that additional funds will be available on satisfactory terms, or at all, to fund such activities.

15

        A summary of our outstanding long-term debt and operating lease contractual obligations at August 31, 2003 is as follows (in thousands):

Contractual Cash Obligations	Total Amounts Committed		Less than 1 Year		1-3 Years		4-5 Years		After 5 Years
Long-term debt	$	4,944	$	4,556	$	388	$	—	$	—
Operating leases		26,796		4,208		5,918		5,618		11,052
Total obligations	$	31,740	$	8,764	$	6,306	$	5,618	$	11,052

Critical Accounting Policies and Estimates

        In preparing our consolidated financial statements, we make assumptions, estimates and judgments that affect the amounts reported. We periodically evaluate our estimates and judgments related to valuation of inventories, allowances for doubtful accounts, notes receivable and sales returns, valuation of deferred tax assets and recoverability of long-lived assets. Note 1 to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended May 31, 2003, filed with the Securities Exchange Commission, describes the accounting policies governing each of these matters. Our estimates are based on historical experience and on our future expectations that are believed to be reasonable. The combination of these factors forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results are likely to differ from our current estimates and those differences may be material.

        We believe the following critical accounting policies affect our more significant estimates and judgements used in preparation of our consolidated financial statements:

•

We provide an inventory reserve for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs would be required.



•

We maintain allowances for doubtful accounts, notes receivable and sales returns for estimated losses resulting from known customer exposures, including product returns and inability to make payments. We also consider collateral values and other factors in evaluating collectibility of notes receivable. Actual results may differ, resulting in adjustment of the respective allowance(s).



•

We currently have deferred tax assets resulting from certain loss carryforwards and other temporary differences between financial and income tax reporting. These deferred tax assets are subject to periodic recoverability assessments. The realization of these deferred tax assets is primarily dependent on future operating results. To the extent we are uncertain whether future operations will generate sufficient profit to utilize the loss carryforwards, valuation allowances are established.



•

We have significant intangible assets, including trademarks, patents and goodwill. The determination of related estimated useful lives and whether or not these assets are impaired involves significant judgements. Changes in strategy or market conditions could significantly impact these judgements and require adjustments to recorded asset balances.

Impact of Inflation

        Historically, we have been able to pass inflationary increases for raw materials and other costs onto our customers through price increases and we anticipate that we will be able to continue to do so in the future.

16

Seasonality

        Our business can be seasonal, with fluctuations in sales resulting from timing of marketing and promotional activities, customer buying patterns and consumer spending patterns. In addition, as a result of changes in product sales mix and other factors, as discussed above, we experience fluctuations in gross profit and operating margins on a quarter-to-quarter basis.

Forward Looking Statements

        Investors are cautioned that, except for the historical information contained herein, the matters discussed in this Quarterly Report contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management's beliefs and assumptions, current expectations, estimates, and projections. Statements that are not historical facts, including without limitation statements which are preceded by, followed by or include the words "believes," "anticipates," "plans," "expects," "estimates," "may," "should" or similar expressions are forward-looking statements. These statements are subject to risks and uncertainties, certain of which are beyond our control, and, therefore, actual results may differ materially.

        Important factors that may cause these forward looking statements to be false include, but are not limited to:

•

the inability to successfully and cost effectively implement initiatives to our Schiff® Move Free® business against the competition;



•

the inability to achieve cost savings and operational efficiencies;



•

the inability to increase operating margins and increase revenues;



•

dependence on individual products and customers;



•

the inability to successfully restructure the Haleko business unit and make it profitable;



•

the impact of competitive products and pricing (including private label);



•

market and industry conditions, including pricing, demand for products, level of trade inventories and raw materials availability and pricing;



•

the success of product development and new product introductions into the marketplace;



•

changes in laws and regulations, including recently proposed FDA regulations regarding good manufacturing practices;



•

litigation and government regulatory action;



•

lack of available product liability insurance for products containing ephedra;



•

adverse publicity regarding the consumption of nutritional supplements;



•

changes in accounting standards; and



•

other factors indicated from time to time in our SEC reports, copies of which are available upon request from our investor relations department or may be obtained at the SEC's website (www.sec.gov).

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

        The following discussion involves forward-looking statements of market risk which assume for analytical purposes that certain adverse market conditions may occur. Actual future market conditions

17

may differ materially from such assumptions. Accordingly, the forward-looking statements should not be considered our projections of future events or losses.

        Our cash flows and net earnings (losses) are subject to fluctuations resulting from changes in interest rates and foreign exchange rates. We currently are not party to any significant derivative instruments and our current policy does not allow speculation in derivative instruments for profit or execution of derivative instrument contracts for which there are no underlying exposure. We do not use financial instruments for trading purposes.

        We measure market risk, related to our holdings of financial instruments, based on changes in interest rates utilizing a sensitivity analysis. We do not believe that a hypothetical 10% change in interest rates would have a material effect on our pretax earnings or cash flows.

ITEM 4. CONTROLS AND PROCEDURES

        We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures.

        As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, the Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures were effective at the reasonable assurance level.

        There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

18

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

        The information set forth in Note 8 to Condensed Consolidated Financial Statements in Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.

Item 2. Changes in Securities.

        Not applicable.

Item 3. Defaults Upon Senior Securities.

        Not applicable.

Item 4. Submission of Matters to a Vote of Security Holders.

        Not applicable.

Item 5. Other Information.

        Not applicable.

Item 6. Exhibits and Reports on Form 8-K

(a)

Exhibits



31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act



31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act



32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act



(b)

Reports on Form 8-K

On August 14, 2003, we filed a report on Form 8-K with the commission regarding our fiscal 2003 fourth quarter and year-end earnings press release.

19

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	WEIDER NUTRITION INTERNATIONAL, INC.
Date: October 7, 2003	By:	/s/  BRUCE J. WOOD      Bruce J. Wood President, Chief Executive Officer and Director
Date: October 7, 2003	By:	/s/  JOSEPH W. BATY      Joseph W. Baty Executive Vice President and Chief Financial Officer

20

QuickLinks

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

WEIDER NUTRITION INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data)
WEIDER NUTRITION INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share data) (unaudited)
WEIDER NUTRITION INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars in thousands) (unaudited)
WEIDER NUTRITION INTERNATIONAL, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except share data) (unaudited)

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 4. CONTROLS AND PROCEDURES

PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
Item 2. Changes in Securities.
Item 3. Defaults Upon Senior Securities.
Item 4. Submission of Matters to a Vote of Security Holders.
Item 5. Other Information.
Item 6. Exhibits and Reports on Form 8-K

SIGNATURES